TScan Therapeutics
TCRX
80 hedge funds and large institutions have $242M invested in TScan Therapeutics in 2024 Q2 according to their latest regulatory filings, with 31 funds opening new positions, 19 increasing their positions, 14 reducing their positions, and 16 closing their positions.
94% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 16
36% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 14
21% more funds holding
Funds holding: 66 → 80 (+14)
6.67% more ownership
Funds ownership: 78.64% → 85.31% (+6.7%)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
11% less capital invested
Capital invested by funds: $272M → $242M (-$29.9M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$21.8M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$7.41M |
| 3 |
SC
Stempoint Capital
New York
|
+$6.66M |
| 4 |
LP
LMR Partners
London,
United Kingdom
|
+$5.24M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
+$3.94M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$2.87M |
| 2 |
LCM
Laurion Capital Management
New York
|
-$2.38M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$2.37M |
| 4 |
Goldman Sachs
New York
|
-$1.77M |
| 5 |
Citigroup
New York
|
-$854K |
TCRX Hedge Fund Activity: Q2 2024 in Review
80 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in TScan Therapeutics (TCRX) for Q2 2024, worth a combined $242M — down 11% from $272M a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new TCRX positions and 16 closed out — a net gain of 15 holders — while 19 added to existing stakes and 14 trimmed.
The largest buyer was BlackRock, adding an estimated $21.8M. The largest seller was Millennium Management, cutting an estimated $2.87M.
- 80 institutional investors held TScan Therapeutics (TCRX) as of Q2 2024, up from 66 in Q1 2024.
- Funds reported $242M of TScan Therapeutics stock for Q2 2024, down 11% quarter-over-quarter.
- 31 funds opened new TScan Therapeutics positions in Q2 2024 and 16 closed out, a net change of +15 holders.
- The largest TScan Therapeutics buyer in Q2 2024 was BlackRock, an estimated $21.8M added.
- The largest TScan Therapeutics seller in Q2 2024 was Millennium Management, an estimated $2.87M sold.
Based on aggregated 13F filings for Q2 2024.